172 related articles for article (PubMed ID: 22642192)
1. Hydroxamic acids as matrix metalloproteinase inhibitors.
Verma RP
Exp Suppl; 2012; 103():137-76. PubMed ID: 22642192
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
[TBL] [Abstract][Full Text] [Related]
3. Progress in the development of matrix metalloproteinase inhibitors.
Tu G; Xu W; Huang H; Li S
Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors.
Nuti E; Tuccinardi T; Rossello A
Curr Pharm Des; 2007; 13(20):2087-100. PubMed ID: 17627541
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
[TBL] [Abstract][Full Text] [Related]
7. Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs).
Rangasamy L; Geronimo BD; Ortín I; Coderch C; Zapico JM; Ramos A; de Pascual-Teresa B
Molecules; 2019 Aug; 24(16):. PubMed ID: 31426440
[TBL] [Abstract][Full Text] [Related]
8. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
Levin M; Udi Y; Solomonov I; Sagi I
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).
Li X; Wu JF
Recent Pat Anticancer Drug Discov; 2010 Jun; 5(2):109-41. PubMed ID: 19951249
[TBL] [Abstract][Full Text] [Related]
10. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.
Lin H; Xu P; Huang M
Future Med Chem; 2022 Jan; 14(1):35-51. PubMed ID: 34779649
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase inhibitors: current developments and future perspectives.
Hoekstra R; Eskens FA; Verweij J
Oncologist; 2001; 6(5):415-27. PubMed ID: 11675519
[TBL] [Abstract][Full Text] [Related]
12. MMP inhibitors and cancer treatment trials, limitations and hopes for the future.
Tlatli R; El Ayeb M
Arch Inst Pasteur Tunis; 2013; 90(1-4):3-21. PubMed ID: 26012207
[TBL] [Abstract][Full Text] [Related]
13. Bioactives from Marine Organisms and their Potential Role as Matrix Metalloproteinase Inhibitors.
Thomas NV; Monica Diyya AS; Kim SK; Faraj KA; Ghafoor DD; Qian ZJ; Tigabu BM
Curr Pharm Des; 2022; 28(41):3351-3362. PubMed ID: 36411577
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges.
Shi Y; Ma X; Fang G; Tian X; Ge C
NanoImpact; 2021 Jan; 21():100293. PubMed ID: 35559782
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases.
Sang QX; Jin Y; Newcomer RG; Monroe SC; Fang X; Hurst DR; Lee S; Cao Q; Schwartz MA
Curr Top Med Chem; 2006; 6(4):289-316. PubMed ID: 16611144
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects.
Zhang C; Kim SK
Mar Drugs; 2009 Mar; 7(2):71-84. PubMed ID: 19597572
[TBL] [Abstract][Full Text] [Related]
17. A quantitative structure-activity relationship study on matrix metalloproteinase inhibitors: piperidine sulfonamide aryl hydroxamic acid analogs.
Kumaran S; Gupta SP
J Enzyme Inhib Med Chem; 2007 Feb; 22(1):23-7. PubMed ID: 17373543
[TBL] [Abstract][Full Text] [Related]
18. A comparative QSAR study on carbonic anhydrase and matrix metalloproteinase inhibition by sulfonylated amino acid hydroxamates.
Gupta SP; Maheswaran V; Pande V; Kumar D
J Enzyme Inhib Med Chem; 2003 Feb; 18(1):7-13. PubMed ID: 12751815
[TBL] [Abstract][Full Text] [Related]
19. Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.
Hugenberg V; Riemann B; Hermann S; Schober O; Schäfers M; Szardenings K; Lebedev A; Gangadharmath U; Kolb H; Walsh J; Zhang W; Kopka K; Wagner S
J Med Chem; 2013 Sep; 56(17):6858-70. PubMed ID: 23899323
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies.
Chau I; Rigg A; Cunningham D
Crit Rev Oncol Hematol; 2003 Feb; 45(2):151-76. PubMed ID: 12604127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
